- Home
- CEVA vs ANAB Comparison
CEVA vs ANAB Comparison
Compare CEVA & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEVA
- ANAB
- Stock Information
- Founded
- CEVA 1999
- ANAB 2005
- Country
- CEVA United States
- ANAB United States
- Employees
- CEVA N/A
- ANAB N/A
- Industry
- CEVA Semiconductors
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- CEVA Technology
- ANAB Health Care
- Exchange
- CEVA Nasdaq
- ANAB Nasdaq
- Market Cap
- CEVA 555.0M
- ANAB 630.2M
- IPO Year
- CEVA 2000
- ANAB 2017
- Fundamental
- Price
- CEVA $26.63
- ANAB $19.66
- Analyst Decision
- CEVA Strong Buy
- ANAB Buy
- Analyst Count
- CEVA 5
- ANAB 10
- Target Price
- CEVA $35.60
- ANAB $48.00
- AVG Volume (30 Days)
- CEVA 243.7K
- ANAB 494.0K
- Earning Date
- CEVA 11-06-2025
- ANAB 11-04-2025
- Dividend Yield
- CEVA N/A
- ANAB N/A
- EPS Growth
- CEVA N/A
- ANAB N/A
- EPS
- CEVA N/A
- ANAB N/A
- Revenue
- CEVA $106,353,000.00
- ANAB $123,164,000.00
- Revenue This Year
- CEVA $4.35
- ANAB $11.40
- Revenue Next Year
- CEVA $15.50
- ANAB $8.17
- P/E Ratio
- CEVA N/A
- ANAB N/A
- Revenue Growth
- CEVA 7.71
- ANAB 304.17
- 52 Week Low
- CEVA $18.31
- ANAB $12.21
- 52 Week High
- CEVA $38.94
- ANAB $39.50
- Technical
- Relative Strength Index (RSI)
- CEVA 71.56
- ANAB 39.84
- Support Level
- CEVA $24.07
- ANAB $17.11
- Resistance Level
- CEVA $24.88
- ANAB $20.40
- Average True Range (ATR)
- CEVA 0.87
- ANAB 1.39
- MACD
- CEVA 0.34
- ANAB -0.12
- Stochastic Oscillator
- CEVA 88.58
- ANAB 36.58
About CEVA CEVA Inc.
CEVA Inc is a licensor of signal-processing intellectual property. Through partnerships with semiconductor companies and original equipment manufacturers globally, the company helps produce devices for a range of end markets. OEMs and semiconductor companies choose to sell products with CEVA equipment to wireless, consumer, automotive, and Internet of Things companies. Revenue is derived primarily from licensing fees and related revenue, and royalties generated from the shipments of products utilizing its intellectual properties. CEVA also engages in the training and sale of development systems.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).